WO2005032535A1 - 神経再生促進剤 - Google Patents
神経再生促進剤 Download PDFInfo
- Publication number
- WO2005032535A1 WO2005032535A1 PCT/JP2004/014879 JP2004014879W WO2005032535A1 WO 2005032535 A1 WO2005032535 A1 WO 2005032535A1 JP 2004014879 W JP2004014879 W JP 2004014879W WO 2005032535 A1 WO2005032535 A1 WO 2005032535A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nerve
- cells
- group
- acid
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a nerve regeneration promoter useful as a medicament.
- Neural stem cells are cells that are capable of self-renewal and have the potential to produce pluripotent cells that can generate neural cells (neurons) and supporting cells such as astrocytes and oligodendrocytes.
- Nerve cells are usually formed from undifferentiated neural stem cells via neural progenitor cells. It is also known that embryonic stem cells (ES cells) and bone marrow cells (bone marrow stem cells, etc.) can be differentiated into nerve cells.
- ES cells embryonic stem cells
- bone marrow cells bone marrow stem cells, etc.
- technologies that are leading in the field of regenerative medicine for example, technologies for regenerating bone and skin tissue, can achieve a certain purpose by reproducing the physical state of the original tissue.
- nerve regeneration in order to use nerve regeneration as a medical technology, it is not enough to physically form nerve cells, but how to mature these nerve cells and how to make them function is an important issue. is there.
- Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Huntington's disease are diseases in which nerve cell death occurs progressively. At present, treatments for these neurodegenerative diseases mainly compensate for neurotransmitter depletion. Replacement therapy or symptomatic treatment is being performed. However, replacement therapy and symptomatic therapy cannot completely suppress the progression of neurodegeneration, and the disease progresses. However, even in the case of such diseases, it is known that endogenous neural stem cells present in the adult brain are differentiated into neural cells. For example, it has been reported that neural regeneration occurs from neural stem cells in an ischemic model animal [Journal of Neurosci., Vol. 18, 7768-7778, 1998].
- 2-propylpentanoic acid derivatives have an astrocyte function-improving effect, and thus are used as therapeutic agents for neurodegenerative diseases, neurological dysfunction after stroke or cerebrospinal trauma, brain tumors, cerebrospinal diseases associated with infectious diseases, and / or the like. It has been reported to be useful as a prophylactic agent (see, for example, EP-A-0632088).
- neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease are serious diseases that cause neurological deficits
- any effective treatment that is not a symptomatic treatment.
- a neurodegenerative disease is one in which axonal transection only occurs, as in the animal model described in Non-Patent Document 2, administration of 2-propylpentanoic acid may be an effective treatment.
- neurodegenerative disease is a generic term for diseases in which not only axons but also nerve cells themselves die gradually, and no specific treatment has been found.
- stem cell transplantation or activation of endogenous stem cells which can be an effective treatment for neurodegenerative diseases, a technology has been found that leads transplanted stem cells or endogenous stem cells to actually functioning neurons. Absent.
- neurodegenerative diseases (1) neurotrophic factor-like action, (2) neurotrophic factor activity enhancing action, (3) nerve (4) a compound having a nerve cell regeneration-promoting action after neurodegeneration (for example, (a) a compound that promotes the formation, proliferation, and differentiation of neural stem cells and neural progenitor cells; ) Neural stem cells, neural progenitor cells, or compounds that promote the engraftment, differentiation, and proliferation of transplanted cells when transplanted, or (c) compounds that promote neuronal maturation) Presumed to be useful.
- a nerve cell regeneration-promoting action after neurodegeneration for example, (a) a compound that promotes the formation, proliferation, and differentiation of neural stem cells and neural progenitor cells; ) Neural stem cells, neural progenitor cells, or compounds that promote the engraftment, differentiation, and proliferation of transplanted cells when transplanted, or (c) compounds that promote neuronal maturation
- the present inventors have conducted intensive studies on the nerve regeneration-promoting effect of the compound of the present invention.
- the compound of the present invention not only promotes proliferation and differentiation of stem cells, neural progenitor cells, etc., but also has an effect on astrocyte.
- the present inventors have found that they have a truly surprising action of promoting the differentiation of glial cells into neurons, and completed the present invention.
- 2-propylpentanoic acid derivative compound has an action of improving astrocyte function, and is used to convert astrocyte to reactive astrocyte. That the compound inhibits the induction of astrocytes.
- the compound has a differentiation-inducing effect, and the present invention is completely unexpected from the above-mentioned patent document.
- the present invention provides: 1. a nerve regeneration promoter comprising a fatty acid compound (excluding retinoic acid and a prostaglandin compound), a salt thereof or a prodrug thereof; 3.
- the above-mentioned 1 wherein the fatty acid compound is a branched fatty acid compound 5.
- the fatty acid compound is represented by the general formula ( I)
- R 1 represents a hydroxy group
- R 2 and R 3 each independently represent (a) a hydrogen atom, (b) a chlorine atom, (c) a C 3-10 alkyl group, (d ) C3-10 alkenyl group, ( e ) C2-10 alkoxy group, () C2-10 alkylthio group, (g) C3-7 cycloalkyl group, (h) phenyl group, (i) phenoxy Group, (j) (C 2-10 alkyl substituted with one or two chlorine atoms) — CH 2 — group, (k) (C 1-4 alkoxy group, C 3-7 cycloalkyl group, phenyl C 1-5 alkyl substituted with one or two substituents selected from a group or a phenoxy group) a CH 2 — group, (1) (where one carbon atom is 1 to 3 fluorine atoms substituted C 1 to 10 alkyl) -CH 2 - group, or (m) or represents
- R 4 is , C 2-3
- the fatty acid compound is represented by (1) 2-propyloctanoic acid, (2) (2R) — 2—Propyloctanoic acid, (3) (2 S) —2— Propyloctanoic acid, (4) 2-propylpentanoic acid, (5) (2R) —7-oxo—2-propyloctanoic acid, (6) (2R, 7R) — 7-hydroxy-2-propyloctanoic acid (7) (2R, 7S) —7-hydroxy-12-propyl octanoic acid or (8) (2R) —8-hydroxy-12-propyloctanoic acid 8.
- the stem cells are embryonic stem cells, bone marrow stem cells, or neural stem cells.
- the nerve regeneration-promoting agent according to the above 10 which is a stem cell, a neural progenitor cell, or a neural cell endogenous cell;
- the nerve regeneration-promoting agent according to any one of the above 1 to 8, wherein the nerve is a central nerve or a peripheral nerve; 17.
- Promote nerve regeneration in a mammal comprising administering to the mammal an effective amount of the compound described in any one of 1 to 8 above, a salt thereof, or a prodrug thereof. 22.
- a method for preparing cells for transplantation which comprises adding a compound, a salt thereof, or an effective amount of a prodrug thereof to any one of the above-described items.
- the present invention relates to a method for producing transplant cells, which is added to a medium containing neural stem cells for transplantation, neural progenitor cells for transplantation, or neural cells for transplantation.
- neural regeneration includes both the terms “neurogenesis” and “neural regeneration” used in the art. That is, the production of the compound of the present invention Any increase in the number of nerve cells and / or mature nerve cells in vivo or in the medium by administration to the body or addition to the culture medium for cultured cells is all included in the nerve regeneration in the present invention.
- nerve regeneration can be classified into quantitative nerve regeneration and qualitative nerve regeneration.
- Quantitative nerve regeneration means an increase in the number of nerve cells
- qualitative nerve regeneration means an increase in mature nerve cells.
- the mature nerve cell means a mature nerve cell, that is, a nerve cell that has grown into a functionally working state such as signal exchange. These nerve regenerations may occur in the living body or may occur outside the living body.
- quantitative nerve regeneration in the living body for example, quantitative nerve regeneration in the living body “Nerve tissue regeneration” and qualitative nerve regeneration in a living body can also be called “nerve function regeneration”.
- nerve regeneration includes, in addition to the above-mentioned increase in the number of nerve cells and mature nerve cells, the meaning of at least partially reproducing the process of normal development in nerves.
- the process of engraftment, differentiation, proliferation, and Z or maturation of neurons or cells that are known to become mature neurons or cells that are known to become cells (hereinafter, regenerating cells)
- regenerating cells When at least one is induced, it is all included in nerve regeneration in the present invention.
- nerve regeneration is not limited by the type and origin of the regenerating cells.
- Regenerating cells include, for example, stem cells (eg, neural stem cells, embryonic stem cells, bone marrow cells, etc.), neural progenitor cells, neural cells, and the like. These cells may be endogenous cells or exogenous cells (eg, transplanted cells, etc.). As exogenous cells, mature neurons can be used. Exogenous cells can be autologous cells but not allogeneic cells Cells. Furthermore, even if the cells are more undifferentiated than neural stem cells, all the cells that differentiate through neural stem cells are included in the neural regeneration of the present invention.
- neural stem cells eg, glial cells (eg, astrocytes, oligodendrocytes, microglia, ependymal cells, etc.), glial progenitor cells, etc.)
- glial cells eg, astrocytes, oligodendrocytes, microglia, ependymal cells, etc.
- glial progenitor cells etc.
- any differentiation into nerve cells or mature nerve cells is included in nerve regeneration in the present invention.
- nerve regeneration may be based on any mechanism.
- it may be based on a neurotrophic factor-like action or a neurotrophic factor activity enhancing action.
- the neurotrophic factor means, for example, a factor that acts as a nutrient for neural stem cells, neural progenitor cells, nerve cells, mature nerve cells, and the like.
- proteins such as NGF (Nerve Growth Factor), BDNF (Brain Derived Neurotrophic Factor), and insulin-like growth factor have been known.
- the neurotrophic factor-like action may be any action such as these neurotrophic factors, such as an axonal elongation action, an action to promote the synthesis of neurotransmitters, an action to promote the differentiation and proliferation of nerve cells, These include, but are not limited to, a nutrient function for maintaining cell activity, a synapse forming action, and a nerve cell protecting action.
- the term “enhancement effect on neurotrophic factor activity” means an activity that enhances the action of the above-described neurotrophic factor.
- neural stem cells, neural progenitor cells, neural cells, and the like for transplantation existing in a living body or taken out of a living body can be proliferated and Z or differentiated into cells having a more advanced differentiation stage.
- neural stem cells are neural progenitor cells, neural cells, mature neural cells, functional neural cells, etc.
- neural progenitor cells are neural cells, mature neural cells, functional neural cells, etc.
- neural cells are mature neural cells.
- Cells, functional nerve cells, etc. can be proliferated and Z or differentiated.
- the method of discriminating these cells can be performed by a known method.For example, these cells are detected by using as an index a protein, mRNA, or the like that is characteristically expressed according to each differentiation stage. Is preferred.
- Such indices include, for example, Nestin and the like for neural stem cells, PSA-NCAM and Doublecortin for neural progenitor cells, and 3III-tubulin (Tuj 1) for neural cells.
- MAP2, NeuN, NSE and the like can be used for mature neurons, and GABA and the like can be used for functional neurons.
- nerve cells and some neural progenitor cells are sometimes referred to as immature nerve cells in the sense of non-mature nerve cells.
- the method for culturing cells for transplantation in the present invention is characterized by adding the compound of the present invention to a medium
- the culture conditions for the basal medium and other additives are determined by using known techniques. Just fine. Specific culture conditions include, for example, the method described in Examples below.
- the method for culturing cells for transplantation in the present invention may be any method as long as the compound of the present invention and the cells for transplantation are brought into contact in any process during the culture period, and is limited by the length of the contact period. is not.
- the method for culturing cells for transplantation in the present invention can also obtain more excellent effects when combined with other known techniques.
- a method of preparing a large amount of neural stem cells by applying electrical stimulation or other physical or chemical stimulation to embryonic stem cells or the like is known.
- neuronal cells obtained by such a method are known.
- the fatty acid compound is not particularly limited as long as it is a chain compound having one carboxy group.
- the chain compound is carboxy
- a compound in which the carbon atom to which the group is attached is a constituent atom of a carbon chain.
- the carbon chains in the fatty acid compound may be saturated or unsaturated, and may be linear or branched. Fats having such carbon chains
- the acid compound may be a saturated fatty acid compound, an unsaturated fatty acid compound, a linear fatty acid compound, or a branched fatty acid compound, respectively.
- the prostaglandin compound is a monocarboxylic acid having 20 carbon atoms and represents a compound having the following basic skeleton.
- the C 1-4 alkoxy group means, for example, a methoxy, ethoxy, propoxy, butoxy group and an isomer thereof.
- the C1-4 alkyl group means, for example, methyl, ethyl, propyl, butyl and isomers thereof.
- the 4- to 7-membered heterocyclic ring containing one nitrogen atom includes, for example, pyrrole, pyridine, azepine or a partially or completely saturated ring (for example, pyrrolidine, pyridine). Lysine, etc.).
- a 4- to 7-membered saturated heterocycle containing one or two nitrogen atoms is, for example, azetidine, pyrrolidine, piperidine, perhydrazepine, It refers to virazolidine, imidazolidin, perhydrazine (eg, piperazine, etc.), perhydrazine zepin, and the like.
- a 4- to 7-membered saturated heterocycle containing one nitrogen atom and one oxygen atom together with the nitrogen atom to which they are bonded is, for example, oxazolidin, perhydroxoxazine (for example, morpholine and the like) ), Perch Droki Means sazepine and the like.
- the amino acid residues represented together with the nitrogen atom to which they are attached may be any amino acid residues, in which a carboxy group is converted to an ester. Also included. Specifically, for example, glycine, alanine, serine, cystine, cystine, threonine, valine, methionine, leucine, isoleucine, nonoleucine, pheninolealanine, tyrosine, thyronine, proline, hydroxyproline, tryptophan, asparaginic acid, Examples include glutamic acid, arginine, lysine, ordinine, histidine residues, and esters thereof (eg, C 1-4 alkyl esters, benzyl esters, etc.).
- the C1-I0 alkyl group in which one carbon atom is substituted by one to three fluorine atoms is, for example, methyl, ethyl, propyl, butyl, pentyl, hexinole, heptyl, octyl , Nonyl, decinole, and isomers thereof, in which one carbon atom is replaced by one, two or three fluorine atoms.
- the C3-l0 benzoquinole group means, for example, propyl, butyl, pentynole, hexinole, heptinole, octyl, nonyl, decyl group and isomer groups thereof.
- the C 3-10 alkenyl group means, for example, propenyl, butyr, pentenyl, hexeninole, hepteninole, otatul, nonenol, decenyl and isomers thereof. .
- the C2-10 alkoxy group means, for example, an ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy group and isomer groups thereof.
- the C 2-10 alkylthio group includes, for example, ethylthio, It means propinorethio, butylthio, pentinorethio, hexinorethio, heptinorethio, octylthio, nonylthio, decylthio, isomers thereof, and the like.
- the C3-7 cycloalkyl group means, for example, a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl group and the like.
- the C2-10 alkyl group means, for example, ethyl, propyl, butynole, pentinole, hexyl, heptyl, octinole, noninole, decyl group and isomers thereof.
- the C2-3 alkyl group means, for example, an ethyl, propyl, or isopropyl group.
- the term "oxidized" in the oxidized C2-3 alkyl group or the oxidized C3-10 alkyl group means that the alkyl group has 1 to 3 hydroxyl groups or oxo groups. It means that it has been replaced.
- the oxy group and the hydroxyl group may be substituted with the same carbon atom only in the case of the terminal carbon atom of the alkyl group.
- the C1-5 alkyl group means, for example, a methyl, ethyl, propyl, butyl, pentyl group and isomer groups thereof.
- the C3-10 alkylidene group means, for example, propylidene, butylidene, pentylidene, hexylidene, heptylidene, octylidene, nonylidene, decylidene group and isomer groups thereof.
- the alkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the alkylthio group, the alkylene group, the alkenylene group and the alkynylene group include straight-chain and branched-chain ones.
- isomers E, Z, cis, trans
- isomers due to the presence of asymmetric carbon R, S, ⁇ ,] 3 configuration, enantiomers, diastereomers
- D, L, d, 1 form optical rotation
- polar form by chromatographic separation high polar form, low polar form
- equilibrium compound rotamer, mixture of any ratio of these, racemic mixture All are included in the present invention.
- the symbol ",” indicates that the bond is to the other side of the page (that is, the ⁇ -configuration), and the symbol "0" indicates that this side is closer to the page (that is, ⁇ ).
- 3-configuration indicates that it is ⁇ -configuration,] 3-configuration or a mixture thereof, and indicates that it is a mixture of ⁇ -configuration and] 3-configuration.
- the salts of the compounds of the present invention include all pharmacologically acceptable salts
- the pharmacologically acceptable salts are preferably non-toxic and water-soluble salts.
- Salts of alkali metals eg, potassium, sodium, lithium, etc.
- salts of alkaline earth metals eg, calcium, magnesium, etc.
- ammonium salts eg, tetramethylammonium salt, Trapylammonium salts, etc.
- organic amines for example, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzamine, phenethylamine, pyridine, monoethanolamine, diethanolamine, trisamine) (Doxymethyl) methylamine, lysine, arginine, ⁇ -methyl-1-D-glucamine, etc.
- acid addition salts eg, inorganic acid salts (eg, hydrochloride, hydrobromide, hydroiodide, Sulfates, phosphates, nitrates, etc.), organic acid salts (eg, acetate, trifluoroacetate, lactate, tartrate, oxalate, fum
- the solvates are preferably non-toxic and water-soluble, and suitable solvates include, for example, water and alcohol. And solvates such as ethanol-based solvents (eg, ethanol).
- solvates such as ethanol-based solvents (eg, ethanol).
- the compound of the present invention is converted into a pharmacologically acceptable salt by a known method.
- the prodrug of the compound of the present invention or a salt thereof refers to a compound that is converted into the compound of the present invention or a salt thereof by a reaction with an enzyme, gastric acid, or the like in a living body or in a cultured cell.
- R 1 is a C 1 to C 1 to C 4 substituted with one alkoxy group or [2] phenyl group.
- R 5 and R 6 are each independently a (1) hydrogen atom, (2) a C 1-4 alkyl group, (3) a phenyl group, (4) (i) a C 1-4 alkoxy group or (ii) a phenyl group substituted with a carboxyl group, (5) a 4- to 7-membered heterocycle containing one nitrogen atom, (6) (i) phenyl A group selected from the group consisting of (ii) a phenyl group substituted with an alkoxy group or a carboxyl group, or (iii) a 4- to 7-membered heterocyclic ring containing one nitrogen atom.
- a C 1-4 alkyl group (7) together with the nitrogen atom to which they are attached, a 4- to 7-membered saturated heterocycle containing one or two nitrogen atoms, (8) they are attached A 4- to 7-membered saturated heterocycle containing one nitrogen atom and one oxygen atom together with a nitrogen atom, or (9) a compound that is an amino acid residue together with a nitrogen atom to which they are bound
- the amino group 1S thereof for example, a compound which is acylated, alkylated, phosphorylated, etc.
- the amino group of the compound represented by (I) or a salt thereof is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-12-oxo-1,3, dioxolen-14-yl) methoxycarbonyl , Tetrahydrofuranylation, pyrrolidylmethylation, bivaloyloxymethylation, acetoxymethylation, tert-butylated compounds, etc.); compounds of the present invention If other the salt thereof have a hydroxyl group, the hydroxyl group thereof is, for example, represented by Ashiru, alkylation, phosphorylation or boration like compounds (e.g., formula (I) A compound of the present invention or a salt thereof, wherein the hydroxyl group of the compound or a salt thereof is acetylated, palmitoylated, propanolylated, bivaloylated, succinylated, fumarylated, alanylated, dimethylamin
- Phenylethyl esterification carboxymethylesterification, dimethylaminomethylesterification, bivaloyloxymethylesterification, ethoxycarbonyloxyshetylesterification, phthalidylesterification, (5-methyl1-2-oxo1-1, 3-dioxolene 4-methyl) methyl esterification, cyclohexyl Such as carbonylcarbonylethyl esterification and methylamidation, etc.
- These compounds can be produced by a method known per se, or a compound represented by the general formula (I) or a salt thereof.
- the prodrug may be either a hydrate or a non-hydrate.
- R 1 is preferably a prodrug, such as a C 1-4 alkoxy group, in addition to the hydroxy group, and more preferably, for example, a hydroxy group, a methoxy group, an ethoxy group, and the like. Most preferably, it is a hydroxy group.
- any group is preferable, for example, a chlorine atom, a hydrogen atom, a C 3-7 alkyl group or a C 3-7 in which one carbon atom is substituted with one to three fluorine atoms.
- 7 alkyl groups and the like are more preferable, and more preferably, for example, chlorine atom, hydrogen atom, propyl, hexyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, 5,5,5- And a trifluoropentyl group, and most preferably a hydrogen atom, propyl, or hexyl group.
- preferred compounds include, for example, (1) 2-propyloctanoic acid, (2) 2-hexylpent-4-enoic acid, (3) 2-hexyl bent-4-inoic acid, (4) 2-propylpentanoic acid, (5) 2-ethylhexanoic acid, (6) 2-propylheptanoic acid, (7) 2-propylhexanoic acid, (8) 2-Propyldecanoic acid, (9) 2-Propylbento-1-enoic acid, (10) 5-Methyl-2-propylhexanoic acid, (11) 4-Methylenol-2-propylpentanoic acid, (12) 5,5- Dimethyl-2-propylhexanoic acid, (13) 6,6-Dimethinoleic 2-propylheptanoic acid, (14) 5-Ethynole-1-propylheptanoic acid, (15) 7-Methyl-1-propyloc
- the compounds of the present invention are known per se or known methods [for example, compounds represented by the general formula (I) are described in European Patent Publication No. 0632008, WO99 / 58513 pamphlet, WO00 / 48982. No. Breadlet, WO03 / 051852 Pamphlet, WO03 / 097851 pamphlet, etc.], for example, Comprehensive Organic Transformations: A 'Guided. Lalock, John Wiley and Sons, Inc., 1999) LComnrehensive Organic Transiormations: A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999)] , Or by appropriately combining those methods.
- the toxicity of the compound of the present invention was sufficiently low, and it was confirmed that the compound was sufficiently safe for use as a pharmaceutical.
- (2R) _2-propyloctanoic acid did not cause any death at 10 O mg Z kg.
- the compound of the present invention can be used as a substance for promoting the engraftment, differentiation, proliferation and / or maturation of stem cells, neural progenitor cells or neural cells in animals including humans, particularly humans, or as a substance that enhances neurotrophic factor activity or neurotrophic factor. It suppresses nerve cell death and promotes the regeneration and regeneration of nerve tissue and nerve function through the regeneration, regeneration, and / or axonal development of nerve cells. Further, the compound of the present invention is useful for preparing transplantation cells (for example, neural stem cells, neural progenitor cells, neural cells, etc.) from brain tissue, bone marrow, and embryonic or embryonic stem cells.
- transplantation cells for example, neural stem cells, neural progenitor cells, neural cells, etc.
- Parkinson's disease or Parkinson's syndrome Alzheimer's disease, Down's syndrome, amyotrophic lateral sclerosis, familial amyotrophic lateral sclerosis, progressive supranuclear palsy, hunting Ton's disease, spinocerebellar ataxia, dentate nucleus pallidum pallidum-Louis atrophy, olive bridge cerebellar atrophy, basal ganglia degeneration, familial dementia, frontotemporal dementia, senile dementia, diffuse Lewy body disease, striatal-nigral degeneration, chorea-atrophic ataxia, dystonia, Mage syndrome, sporadic cerebellar cortical atrophy, familial spastic paraplegia, motor neuropathy, pine card Diosef's disease, Pick's disease, stroke or cerebrovascular disorder (eg, after cerebral hemorrhage or subarachnoid hemorrhage, or cerebral infarction after cerebral thrombosis or embolism and neurological dysfunction after cerebral infarction
- cerebrovascular disorder
- the compound of the present invention is also useful for preparing cells for transplantation from living organisms, such as brain tissue, bone marrow, and / or embryonic stem cells.
- living organisms such as brain tissue, bone marrow, and / or embryonic stem cells.
- neural stem cells for transplantation neural precursors for transplantation It can be used as an additive when culturing cells, neurons for transplantation, mature neurons for transplantation, etc. in vitro, preferably as an agent for promoting proliferation and differentiation.
- transplantation is not limited to autologous transplantation, and may be allogeneic transplantation.
- Neural stem cells and neural progenitor cells are preferred as cells for transplantation.
- the compound of the present invention can be used for cells that have undergone more advanced stages of differentiation than neural stem cells, in particular, for cells such as glial cells (eg, astrocytes, oligodendrocytes, microdalia, ependymal cells, etc.) and glial progenitor cells. Act on the nerve cells, Furthermore, they can be differentiated into mature neurons. The mechanism of differentiation of these cells into neurons and mature neurons may be any. For example, these glial cells ⁇ glial progenitor cells may undergo neural stem cells And neural progenitor cells, and then differentiate and proliferate into neurons and mature neurons.
- glial cells eg, astrocytes, oligodendrocytes, microdalia, ependymal cells, etc.
- glial progenitor cells Act on the nerve cells, Furthermore, they can be differentiated into mature neurons. The mechanism of differentiation of these cells into neurons and mature neurons may be any. For example, these glial cells ⁇ glial progenitor
- the compound of the present invention In order to use the compound of the present invention for the above-mentioned purposes, it is usually administered systemically or locally in humans and animals in an oral or parenteral form. It is treated by direct injection into the cells. When administered to a living body, it can be administered surgically, for example, directly into the ventricle.
- Dosage varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc.
- oral administration in general, per adult, once per day, from l / ig to 5000 mg per dose It is orally administered once to several times.
- parenteral administration the parenteral administration is performed once to several times daily in the range of 0.1 to 50 Omg per adult per day.
- the parenteral dosage form is preferably intravenous, and is continuously administered intravenously for 1 hour to 24 hours per day.
- cultured cells In the case of cultured cells, it is added to the culture solution in the range of 1 pmo 1 / l to 100 mm o 1, L, or a certain amount is directly injected into the cell in the range of 0.1 fmo 1, L to lOO ju mo 1 ZL. (Eg, microinjection).
- the administration and treatment amount fluctuates depending on various conditions. Therefore, a smaller amount than the above administration and treatment amount may be sufficient, or an administration and treatment beyond the range may be required in some cases. .
- a solid preparation for oral administration a liquid preparation for oral administration, an injection for parenteral administration, an external preparation, a suppository, an eye drop, an inhalant, a nasal agent, etc.
- a suppository an injection for parenteral administration
- an external preparation a suppository
- an eye drop an inhalant
- a nasal agent etc.
- Oral solid dosage forms include tablets, pills, capsules, powders, condyles Granules and the like are included.
- Capsules include hard capsules and soft capsules.
- Tablets include sublingual tablets, buccal patches, buccally disintegrating tablets and the like.
- one or more active substances may be applied as such, or as excipients (eg, lactose, mannitol, darcos, microcrystalline cellulose, starch, etc.), binders (eg, , Hydroxypropylcellulose, polyvinylpyrrolidone, magnesium aluminate metasilicate, etc.), disintegrant (eg, calcium cellulose glycolate, etc.), lubricant (eg, magnesium stearate, etc.), stabilizer, solubilizer (Eg, glutamate, aspartic acid, etc.) and the like, and used in the form of a formulation according to a conventional method.
- excipients eg, lactose, mannitol, darcos, microcrystalline cellulose, starch, etc.
- binders eg, , Hydroxypropylcellulose, polyvinylpyrrolidone, magnesium aluminate metasilicate, etc.
- disintegrant eg, calcium cellulose glycolate,
- a coating agent for example, sucrose, gelatin, hydroxypropinoresenolerose, hydroxypropinolemethinoresenolerose phthalate, etc.
- a coating agent for example, sucrose, gelatin, hydroxypropinoresenolerose, hydroxypropinolemethinoresenolerose phthalate, etc.
- two or more layers May be.
- capsules of absorbable materials such as gelatin.
- Sublingual tablets are prepared according to a known method.
- one or more active substances may include excipients (eg, lactose, mannitol, glucose, microcrystalline cellulose, colloidal silica, starch, etc.), binders (eg, hydroxypropylcellulose, polyvinylpyrrolidone, metasilicate).
- Magnesium aluminate, etc. disintegrants (eg, starch, L-hydroxypropyl senorelose, canoleboxy methinoresenorelose, croscarnomelose sodium, calcium cellulose glycolate, etc.), lubricants (eg, , Magnesium stearate, etc.), swelling agents (for example, hydroxypropylcellulose, hydroxypropylmethylsenorellose, carbopol, forcenoreboxymethylcellulose, polyvinyl alcohol, xanthan gum, guar gum, etc.) ), Swelling aids (eg, gnorecose, phenolicose, mannitol, xylitol, erythritol, maltose, trehalose, phosphate, citrate, silicate, Lysine, glutamic acid, arginine, etc.), stabilizer, dissolution aid (eg, polyethylene glycol, propylene glycol, glutamic acid
- the oral patch is prepared according to a known method.
- one or more active substances may include excipients (eg, lactose, mannitol, darcos, microcrystalline cellulose, colloidal silica, starch, etc.), binders (eg, hydroxypropylcellulose, polybutyl).
- Pyrrolidone, magnesium metasilicate aluminate, etc. disintegrants (for example, starch, L-hydroxypropinoresenorelose, canoleboximetinoresoleolose, cross-force noremelose sodium, calcium cellulose glycolate, etc.), Lubricants (eg, magnesium stearate, etc.), adhesives (eg, hydroxypropylcellulose, hydroxypropylmethylcellulose, carbopol, carboxymethylcellulose, polyvinyl alcohol, xanthan gum, guar gum, etc.
- disintegrants for example, starch, L-hydroxypropinoresenorelose, canoleboximetinoresoleolose, cross-force noremelose sodium, calcium cellulose glycolate, etc.
- Lubricants eg, magnesium stearate, etc.
- adhesives eg, hydroxypropylcellulose, hydroxypropylmethylcellulose, carbopol, carboxymethylcellulose, polyvinyl alcohol, xanthan gum, guar gum
- Adhesion aids eg, glucose, fructose, mannitol, xylitol, erythritol, maltose, trehalose, phosphate, citrate, silicate, glycine, glutamic acid, arginine, etc.
- a coating agent eg, sucrose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate, etc.
- the orally rapidly disintegrating tablet is prepared according to a known method.
- one or more active substances may be used as such or as a suitable coating agent (eg, ethinoresenolerose, hydroxypropinoresenorelose, hydroxypropinolemethyl cellulose, methacrylic acid acrylate copolymer)
- a suitable coating agent eg, ethinoresenolerose, hydroxypropinoresenorelose, hydroxypropinolemethyl cellulose, methacrylic acid acrylate copolymer
- Excipients eg, lactose, mannitol, etc.
- a plasticizer eg, polyethylene glycol, triethyl citrate, etc.
- Glucose microcrystalline cellulose, colloidal silica, starch, etc.
- binders eg, hydroxypropylcellulose, polybutylpyrrolidone, magnesium metasilicate aluminate, etc.
- disintegrants eg, starch, L-hydroxypropiate
- Noresenorelose, Canoleboximetinoresorero Cross-strength melose sodium, cellulose fibrous dalicholate, etc.
- lubricants eg, magnesium stearate, etc.
- dispersing aids eg, glucose, fructose, mannitol, xylitol, erythritol, Manoletose, trehalose, phosphate, citrate, silicate, glycine, glutamic acid, arginine, etc., stabilizers, solubilizers (eg, polyethylene glycol, propylene glycol, glutamic acid, aspartic acid, etc.)
- a coating agent for example, sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, etc.
- a coating agent for example, sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, etc.
- commonly used additives such as preservatives, antioxidants, coloring agents, sweeteners and the like can be added.
- Liquid preparations for oral administration include pharmaceutically acceptable solutions, suspensions, emulsions, syrups, elixirs and the like. In such liquids, Or more active substances are dissolved, suspended or emulsified in commonly used diluents (eg, purified water, ethanol or a mixture thereof). Further, the liquid preparation may contain a wetting agent, a suspending agent, an emulsifying agent, a sweetening agent, a flavoring agent, a fragrance, a preservative, a buffering agent and the like.
- diluents eg, purified water, ethanol or a mixture thereof.
- the liquid preparation may contain a wetting agent, a suspending agent, an emulsifying agent, a sweetening agent, a flavoring agent, a fragrance, a preservative, a buffering agent and the like.
- Topical dosage forms for parenteral administration include, for example, ointments, gels, creams, compresses, patches, liniments, sprays, inhalants, sprays, sols, These include eye drops and nasal drops. It contains one or more of these active substances and is manufactured by known methods or commonly used formulations.
- the ointment is manufactured by a known or commonly used formulation. For example, it is produced by grinding or melting one or more active substances in a base.
- the ointment base is selected from known or commonly used ones. For example, higher fatty acids or higher fatty acid esters (eg, adipic acid, myristic acid, noremitic acid, stearic acid, oleic acid, adipic acid ester, myristic acid ester, olemitic acid ester, stearic acid ester, oleic acid ester, etc.
- Waxes eg, beeswax, spermaceti, ceresin, etc.
- surfactants eg, polyoxyethylene alkyl ether phosphate, etc.
- higher alcohols eg, cetanol, stearyl alcohol, setostearyl alcohol, etc.
- Silicone oil eg, dimethylpolysiloxane, etc.
- hydrocarbons eg, hydrophilic petrolatum, white petrolatum, purified lanolin, liquid paraffin, etc.
- glycols eg, ethylene glycol, diethylene glycol, etc.
- Propylene glycol, polyethylene glycol, macrogonore, etc. vegetable oil (for example, castor oil, olive oil, sesame oil, turpentine, etc.), animal oil (for example, mink oil, egg yolk oil, squalane, squalene, etc.), water, water absorption
- Those selected from accelerators and anti-rash agents are used alone or as a mixture
- the gel is produced by a known or commonly used formulation. For example, it is produced by melting one or more active substances in a base.
- the gel base is selected from known or commonly used ones.
- lower alcohols for example, ethanol, isopropyl alcohol, etc.
- gelling agents for example, carboxymethinoresenorelose, hydroxyshethylcellulose, hydroxypropylcellulose, ethylcellulose, etc.
- neutralizing agents E.g., triethanolamine, diisopropanolamine, etc.
- surfactants e.g., polyethylene glycol monostearate, etc.
- gums water, absorption enhancers, antifoggants, alone or in combination.
- they may contain preservatives, antioxidants, flavoring agents and the like.
- the cream is produced by a known or commonly used formulation. For example, it is prepared by melting or emulsifying one or more active substances in a base.
- the cream base is selected from known or commonly used ones. For example, higher fatty acid esters, lower alcohols, hydrocarbons, polyhydric alcohols (eg, propylene glycol, 1,3-butylendalcol, etc.), higher alcohols (eg, 2-hexyldecanol, cetanol, etc.), emulsifier
- polyoxyethylene alkyl ethers for example, polyoxyethylene alkyl ethers, fatty acid esters, etc.
- water, an absorption promoter, and a rash inhibitor are used alone or in combination of two or more. Further, they may contain preservatives, antioxidants, flavoring agents and the like.
- the poultice is produced by a known or commonly used formulation. For example, it is produced by melting one or more active substances in a base material, spreading the mixture on a support as a kneaded product, and producing the mixture.
- the compress base is selected from known or commonly used ones. For example, thickeners (eg, polyacrylic acid, polyvinylpyrrolidone, gum arabic, starch, gelatin, methylcellulose, etc.), wetting Agents (eg, urea, glycerin, propylene glycol, etc.), fillers (eg, kaolin, zinc oxide, talc, calcium, magnesium, etc.), water, dissolution aids, tackifiers, antifoggants Are used alone or in combination of two or more. Further, they may contain preservatives, antioxidants, flavoring agents and the like.
- thickeners eg, polyacrylic acid, polyvinylpyrrolidone, gum arabic, starch, gelatin, methylcellulose, etc.
- the patch is produced by a known or commonly used formulation. For example, it is produced by melting one or more active substances in a base material, and spreading and coating on a support.
- the base for the patch is selected from those known or commonly used. For example, one selected from a polymer base, oils and fats, higher fatty acids, tackifiers and anti-rash agents may be used alone or as a mixture of two or more. In addition, preservatives, antioxidants, flavoring agents and the like may be included.
- the liniment is manufactured by a known or commonly used formulation.
- one or more actives may be selected from water, alcohols (eg, ethanol, polyethylene glycol, etc.), higher fatty acids, glycerin, soaps, emulsifiers, suspending agents, etc., alone or It is prepared by dissolving, suspending or emulsifying in two or more species. Further, they may contain preservatives, antioxidants, flavoring agents and the like.
- Sprays, inhalants, and sprays may be used in addition to commonly used diluents, as well as buffers that provide isotonicity with stabilizers such as sodium bisulfite, for example, sodium chloride, sodium citrate or quinone. It may contain isotonic agents such as acids. Methods for producing sprays are described in detail, for example, in US Pat. Nos. 2,868,691 and 3,095,355.
- Injections for parenteral administration include all injections. Examples include injections into muscle, intravenous injections, intravenous infusions, and the like.
- Injections for parenteral administration include solutions, suspensions, emulsions, and solid injections that are used by dissolving or suspending in a solvent for use.
- a solvent for example, distilled water for injection, physiological saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol, and a combination thereof are used.
- this injection includes a stabilizer, a dissolution aid (eg, glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.), a suspending agent, an emulsifier, a soothing agent, a buffer, a preservative, and the like. May be included.
- a stabilizer e.g, glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.
- a suspending agent eg.g, glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.
- an emulsifier emulsifier
- a soothing agent e.g., a sterile distilled water
- a sterile distilled water for injection or other solvents before use.
- Inhalants for parenteral administration include aerosols, powders for inhalation, and solutions for inhalation.
- the inhalation solution is used by dissolving or suspending in water or other appropriate medium at the time of use. It may be in a form.
- inhalants are manufactured according to a known method.
- a preservative eg, benzalkonium chloride, paraben, etc.
- a coloring agent e.g, a buffering agent (eg, sodium phosphate, sodium acetate, etc.), a tonicity agent (eg, sodium chloride) , Concentrated glycerin, etc.), a thickener (eg, cariboxyvinyl polymer, etc.), an absorption enhancer, etc., as necessary.
- lubricants eg, stearic acid and its salts, etc.
- binders eg, starch, dextrin, etc.
- excipients eg, lactose, cellulose, etc.
- coloring agents It is prepared by appropriately selecting a preservative (eg, benzalkonium chloride, paraben, etc.), an absorption promoter and the like as needed.
- a nebulizer eg, an atomizer, a nebulizer, etc.
- an inhaler for powdered medicine is usually used to administer an inhalable powder.
- compositions for parenteral administration include suppositories for rectal administration and vaginal administration containing one or more active substances, which are prescribed in a conventional manner. Includes pessaries for giving.
- the compounds of the present invention may be used to (1) complement and / or enhance the preventive and Z or therapeutic effects of the compound, (2) improve kinetics and absorption, reduce dosage, and / or (3) reduce side effects. It may be administered as a concomitant drug in combination with other drugs.
- the compounds of the present invention may be combined and administered as a concomitant drug.
- the concomitant drug of the compound of the present invention and another drug may be administered in the form of a combination preparation in which both components are combined in one preparation. May be administered. When administered in the form of separate preparations, simultaneous administration and administration at different times are included. In addition, the administration at a time difference may be performed by administering the compound of the present invention first and then administering another drug, or administering the other drug first and then administering the compound of the present invention. Each administration method may be the same or different.
- the combination of the present invention exerts a preventive and / or therapeutic effect
- the combination of the present invention complements and prevents the preventive and / or therapeutic effects as compared to those administered alone. Or if it is a disease that enhances.
- drugs used in the concomitant drug of the present invention include, for example, acetylcholinesterase inhibitor, nicotine receptor modulator, amyloid protein production, secretion, accumulation, aggregation and / or deposition inhibitor (eg,] 3 secretase inhibitor , ⁇ -secretase inhibitor, amyloid protein aggregation inhibitor, J3 amyloid pectin, amyloid degrading enzyme, etc., cerebral function activator, other Parkinson's disease drug (eg, dopamine receptor agonist, monoamine oxidase ( ⁇ ⁇ ) Block Harmful drugs, anticholinergic drugs, catechol-1 O-methyltransferase (COMT) inhibitors, etc., drugs for treating amyotrophic lateral sclerosis, cholesterol-lowering drugs, etc.
- Parkinson's disease drug eg, dopamine receptor agonist, monoamine oxidase ( ⁇ ⁇ ) Block Harmful drugs, anticholinergic drugs, catechol-1 O-methyltransferase (COMT
- hyperlipidemia eg, statins, fibrates
- Squalene synthase inhibitor etc.
- treatment for abnormal behavior associated with the progression of dementia, wandering, etc. apoptosis inhibitor, nerve differentiation and regeneration promoter, antihypertensive, antidiabetic, antidepressant, anxiolytic, non Steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, anti-cytokine drugs (eg, TNF inhibitors, MAP kinase inhibitors, etc.), steroid drugs, sex hormones or derivatives thereof, parathyroid hormone (eg, PTH etc.) ), Calcium receptor antagonists and the like.
- acetylcholinesterase inhibitors examples include donezil, rivastigmine, galantamine, zanadizyl (TAK-147) and the like.
- Examples of / 3 secretase inhibitors include 6- (4-biphenylyl) methoxy-2- [2- (N, N-dimethylamino) ethyl] tetralin and 6- (4-biphenylyl) methoxy One 2- (N, N-dimethylamino) methyltetralin, 6- (4-biphenylyl) methoxy-l2_ (N, N-dipropylamino) methyltetralin, 2- (N, N-dimethylamino) methyl-6- (4, —Methoxybiphenyl-1-yl) methoxytetralin, 6— (4-Biphenylyl) methoxy-1 2 -— [2- (N, N-Jetylamino) ethyl] tetralin, 2-—2- (N, N-dimethylamino) ethyl] —6— (4,1-methylbiphenyl) 4 Methoxytetral
- amyloid protein aggregation inhibitory agents examples include ⁇ -00703, ALZHEMED (NC-531), ⁇ -368 (Table 11-514333), ⁇ I-558 (Table 2001-500852), and SKF. -74652 (Biochem. J., 340 (1), 283-289, 1999).
- brain function activator examples include aniracetam, nicergoline and the like.
- Dopamine receptor agonists include, for example, L-dopa, promocrypten, pergolide, talixol, placizoxole, powerbergoline, adamantazine and the like.
- Examples of the monoamine oxidase (MAO) inhibitor include safurazine, deprenyl, sergiline (selegiline), remacemide, and riluzole.
- anticholinergic agents examples include trihexyphenidyl, biperiden and the like.
- catechol-1 O-methyltransferase inhibitor examples include entakapon and the like.
- Examples of the therapeutic agent for amyotrophic lateral sclerosis include riluzole, neurotrophic factor and the like.
- statin-based therapeutic agent for hyperlipidemia examples include pravastatin sodium, atorvastatin, simpastatin, and rospastatin.
- fibrate-based therapeutic agents for hyperlipidemia examples include clofibrate and the like.
- Apoptosis inhibitors include, for example, CII-1189, IDN-6556, CEP-1347 and the like.
- Examples of the neural differentiation regeneration promoter include Leteprinim, Xaliproden (SR-57746-A), SB-216763 and the like.
- nonsteroidal anti-inflammatory drugs examples include meloxicam, teoxicam, indomethacin, ibuprofen, celecoxib, oral fuecoxib, aspirin, indomethacin and the like.
- steroids examples include dexamethasone, hexestrol, cortisone acetate, and the like.
- sex hormone or a derivative thereof examples include progesterone, estradiol, estradiol benzoate, and the like.
- the weight ratio of the compound of the present invention to other drugs is not particularly limited.
- Other drugs may be administered in any combination of two or more.
- other drugs that complement and / or enhance the preventive and / or therapeutic effects of the compound of the present invention may be found not only to date but also to date based on the mechanism described above. Things are also included.
- the compound of the present invention has an effect of promoting nerve regeneration in animals including humans, particularly in humans, and is useful for preventing and / or treating neurodegenerative diseases, and thus can be used as a pharmaceutical.
- nerve cells in the preparation of nerve cells for transplantation outside the body, by using them as culture additives, nerve cells can be obtained efficiently, so that they can be used for preparing cells for pharmaceutical use.
- the compound of the present invention is administered to a living body for the purpose of preventing and treating a neurodegenerative disease and treating endogenous cells.
- Vesicles may be differentiated, proliferated and / or matured, or the compound of the present invention may be administered to a living body after transplanting neural stem cells, neural progenitor cells or neural cells into the living body, and the cells may engraft, differentiate, It may be grown and / or matured.
- the transplanted cells may be cultured in vitro in the presence of the compound of the present invention, and then appropriately differentiated and propagated, and then transplanted into a living body.
- nerve cells and mature nerve cells can be obtained from non-neuronal cells such as glial cells, so that these cells can be prepared in a large amount.
- the present invention does not pose an ethical problem since a large amount of nerve cells and mature neurons can be obtained from own cells or a small number of cell materials collected from the cells.
- FIG. 1 is a graph showing the change in the number of surviving pyramidal neurons in a rat four-vessel ligation (4VO) model administered with (2R) -2-propyloctanoic acid.
- Figure 2 shows the results in DMEM F12 medium containing 1% fetal calf serum (Omoto Pharmaceutical) (compound-free group) and medium containing (2R) -2-propyloctanoic acid (compound-added group).
- FIG. 4 is a micrograph showing changes in the number of (3111) -tubulin-positive cells in a rat embryonic brain-derived stem cell differentiation test cultured for 7 S in (1).
- the compound of the present invention has a nerve regeneration effect and a disease condition improving effect.
- the measuring method for evaluating the compound of the present invention is improved as follows in order to improve the measuring accuracy and / or the measuring sensitivity. The detailed experimental method is shown below.
- Example 1 Examination of the effect on in vivo (in vivo) neural stem cell differentiation 11 A: Evaluation by histological findings
- the rat four-vessel ligation (4VO) model was prepared by partially modifying the method of Prusinelli et al. (J. Cereb Blood Flow Metab, Vol. 16, 973-980, 1979). In other words, bilateral vertebral arteries of male Wistar rats were permanently occluded, and the next day, the common carotid artery was exposed, and a temporary occlusion was performed with a clip for 10 minutes. Immediately after the bilateral common carotid artery occlusion, those who did not respond and lost the righting reflex were used in the experiment.
- the evaluation of nerve cell regeneration was performed by preparing a brain tissue specimen by Nissl staining and counting the number of nerve cells in the left and right hippocampal CA 1 regions. Administration of vehicle (0.1 VO 1% Tween 80) and test compound (10 mg kg) resulted in delayed neuronal death of pyramidal neurons in hippocampal CA1 area. The test was performed by oral gavage once a day.
- the number of pyramidal neurons present in the hippocampal CA1 region was significantly reduced in the vehicle-treated group subjected to forebrain ischemia for 10 minutes compared to the normal group.
- the number of surviving pyramidal neurons was significantly increased compared to the vehicle-treated group.
- FIG. 1 shows the results when (2R) -2-propyloctanoic acid was used as the test compound.
- Example 11 A—Confirmation that pyramidal neurons increased in A-2-1 were regenerated neurons was prepared by preparing a brain tissue specimen immunostained for BrdU and NeuN, The measurement was performed by counting the number of double-staining positive neurons in one region.
- the anti-NeuN antibody was used to detect mature neurons
- Anti-BrdU antibody was used for the purpose of detecting neoplastic cells.
- the administration of the vehicle (0.1 V o 1% Tween 80) and the test compound (lOmgZkg) were performed in the same manner as described above.
- BrdU was administered by intraperitoneal administration (5 Omg / kg) once a day from immediately after blood reperfusion in 4VO treatment to tissue removal.
- the number of double-staining positive neurons was calculated as the number per unit length (mm) using the neuronal layer length in the hippocampal CA 1 region and the number of double-staining positive neurons.
- the double-staining positive cells with the anti-BrdU antibody and the anti-NeuN antibody present in the hippocampal CA1 region significantly increased compared to the vehicle-administered group.
- 1 -B-1 Creation of a rat 4-vessel ligation (4VO) model and drug administration
- Example 1 A rat four-vessel ligation (4VO) model was prepared by the method described in A-1 and subjected to the following tests. The administration of the vehicle (0.1 V o 1% tween 80) and the test compound ((2R)-2-propyloctanoic acid: 1, 3, lOmg / kg) caused pyramidal neurons in the hippocampal CA1 area. From 8 days to 48 days after the 4 VO treatment, which certainly showed late neuronal death, the test was performed by oral gavage five times a week. The group composition is shown in Table 1 below. table 1
- a black circular pool (Niiuro Science Co., Ltd.) with a diameter of 150 cm and a height of 50 cm was used. This pool was filled with tap water at about 23 ° C to a height of about 30 cm (the platform top was about 1 cm below the water surface).
- the goal platform (colorless transparent acrynole: circular with a diameter of 10 cm) was installed so that the distance from the inner wall of the pool was about 35 cm.
- the positions of racks, lighting fixtures, and the clues of the experimenter and others that helped to perceive the space were kept constant, and the lighting level was also kept constant.
- the rats were allowed to stand still at an arbitrary starting position, and the time required to get on the platform (escape latency (sec)) was measured.
- the maximum swimming time for the rat on the platform was 90 seconds.
- the rat got on the platform it was left there for about 30 seconds before returning to the cage. If the rat could not get on the platform within the measurement time of 90 seconds, the rat was taken out of the water, transferred to the platform, left for about 30 seconds, and returned to the cage.
- the escape latency in this case was set to 90 seconds.
- the interval between each trial was about 30 minutes, and four trials were conducted a day, which was one session. This session was held for four consecutive days, (1) Escape latency, and (2) Number of successes (The number of times the platform was reached during the four trials was evaluated.
- control group treated with 4VO had significantly longer escape latencies in the second, third, and fourth sessions compared to the normal group (second, third, and fourth sessions: ⁇ ⁇ 0.001: Wilcoxon rank sum test).
- Control group as compared to the normal group, the second significant difference in the third and fourth sessions were observed (second, third session: p ⁇ 0.05: X 2 test, fourth cell Sshiyon: p 0.001:% 2 test).
- Histopathological specimens consisted of one brain tissue sample, (1) Nissl stained sample (5.7 mm from the Interaural line), (2) Hematoxylin-eosin stained specimen, and (3) Unstained specimen (thickness : 1 ⁇ ⁇ ). Of these samples, the left and right hippocampal CA1 neuron layer length and number of neurons were measured using an image analyzer (MCID Elite 7.0 Rev.1.0) for the Nissl stained specimen, and the number per unit length (mm) was determined. Histological evaluation was performed by calculation.
- Table 4 shows the measurement results of the number of neurons in the hippocampus CA1 region.
- the fetus was removed from a Wistar pregnant rat, and the striatum was removed from the fetal brain.
- the cells are dispersed by pipetting, and the growth medium (N2 supplement (N2Plus supplement, R & D systems), antibiotics, basic fibroblast growth factor (20ng / mL bFGF, R & D systems) and epidermal growth factor (20ng / mL)
- the cells were cultured in a DMEMZF12 medium (Gibco)) containing EGF, R & D systems) for 6 to 7 days.
- the formed neurospheres were collected, the cells were dispersed by pipetting, and the cells were further cultured in a growth medium for 6 to 7 days.
- the cells were seeded on a chamber slide coated with poly-L-orditin. After 24 hours of culture, the medium was replaced with a differentiation medium (DMEMZF 12 medium containing N2 additive, antibiotics and 1% fetal bovine serum) containing the test compound. After differentiation for 7 days, fix with 4% paraformaldehyde and immunize with mouse anti-III-tubulin antibody (secondary antibody: FITC-labeled anti-mouse IgG antibody) that is an indicator of differentiation of neural stem cells into neural cells Staining was performed.
- a differentiation medium DEMZF 12 medium containing N2 additive, antibiotics and 1% fetal bovine serum
- Rat striatum-derived neural stem cells were cultured in DMEM F12 medium containing 1% fetal calf serum (Dainippon Pharmaceutical) (compound-free group) or medium containing test compound Cultured in medium (compound-added group) for 7 days, the number of cells per field of view under a microscope (magnification: 100x)] 3 III-tubulin-positive (Tuj1 +) cells was higher than that in the compound-free group. There was a significant increase in the group. For example, when 30 ⁇ 1ZL of (2R) -2-propylotatanic acid is used, 8 ⁇ 1.3 (8 visual field measurements) in the compound-free group is 31 ⁇ 4.6 (8 visual fields) in the compound-added group. Measurement). The result is shown in figure 2.
- neural stem cells derived from rat striatum With respect to the above neural cells obtained by differentiating neural stem cells derived from rat striatum, the stage of differentiation was confirmed by immunostaining. An anti-MAP2 antibody was used to identify mature neurons, and an anti-GAB A antibody was used to identify functional neurons.
- mature neural cells and functional neurons can be obtained by differentiating rat embryonic striatum-derived neural stem cells into neural cells using a medium supplemented with (2R) -2-propylotatanic acid. I understood.
- Example 3 Examination of the effect on differentiation of primary cultured astrocytes to neurons
- the cerebrum was removed from a newborn Wistar rat, and the meninges were removed under a stereoscopic microscope Thereafter, the suspension was rubbed in an ice-cooled DMEM medium at the frost portion of the slide glass with frost. After centrifugation at 100 ⁇ g for 3 minutes, the precipitate was suspended in 10% fetal calf serum-DMEM medium and seeded in a 75 cm 2 flask. Two days after the start of culture, cell purification was performed.
- astrocytes were collected using 0.05% trypsin / EDTA, and the differentiation medium (N2 supplement (R2D supplement, R & D systems) and 1% fetal serum (Dainippon Pharmaceutical)
- the cells were resuspended using DMEMZF 12 medium (Gibco)).
- the cells were seeded on a chamber slide, and the next day, the culture medium was replaced with a differentiation medium (DMEM / F12 medium containing N2 additive, antibiotics and 1% fetal bovine serum) containing the test compound.
- DMEM / F12 medium containing N2 additive, antibiotics and 1% fetal bovine serum
- the differentiation stage of neurons obtained by differentiating astrocytes derived from rat cerebral cortex was confirmed by immunostaining.
- Anti-] 3III-tubulin antibody and anti-Doublecortin antibody were used to confirm immature nerve cells, anti-MAP2 antibody, anti-NeuN antibody and anti-NSE antibody were used to confirm mature neurons, and functional neurons were used.
- the cells were confirmed using an anti-GAB A antibody.
- astrocytes derived from rat cerebral cortex are differentiated into neurons using a medium supplemented with (2R) -2-pyructylpyructanoic acid, and mature neurons and functional neurons are obtained. It turned out to be obtained.
- the compound of the present invention has a nerve regeneration promoting action in animals including humans, particularly in humans, it is useful for preventing and / or treating neurodegenerative diseases. Available as pharmaceuticals.
- the nerve cell for transplantation is used as a culture additive during the extracorporeal preparation of the nerve cell, the nerve cell can be obtained efficiently, so that it can be used for the preparation of cells for pharmaceutical use.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04792173A EP1685832B1 (en) | 2003-10-03 | 2004-10-01 | Nerve regeneration promoters |
US10/574,479 US8569058B2 (en) | 2003-10-03 | 2004-10-01 | Nerve regeneration promoters |
DE602004032165T DE602004032165D1 (de) | 2003-10-03 | 2004-10-01 | Nervenregenerationsförderer |
AT04792173T ATE504295T1 (de) | 2003-10-03 | 2004-10-01 | Nervenregenerationsförderer |
JP2005514504A JP4715514B2 (ja) | 2003-10-03 | 2004-10-01 | 神経再生促進剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-345123 | 2003-10-03 | ||
JP2003345123 | 2003-10-03 | ||
JP2004162909 | 2004-06-01 | ||
JP2004-162909 | 2004-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005032535A1 true WO2005032535A1 (ja) | 2005-04-14 |
Family
ID=34425346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/014879 WO2005032535A1 (ja) | 2003-10-03 | 2004-10-01 | 神経再生促進剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8569058B2 (ja) |
EP (1) | EP1685832B1 (ja) |
JP (1) | JP4715514B2 (ja) |
AT (1) | ATE504295T1 (ja) |
DE (1) | DE602004032165D1 (ja) |
WO (1) | WO2005032535A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007046347A1 (ja) | 2005-10-18 | 2007-04-26 | Ono Pharmaceutical Co., Ltd. | 筋萎縮性側索硬化症患者の運動神経保護用医薬 |
WO2007102571A1 (ja) | 2006-03-09 | 2007-09-13 | Ono Pharmaceutical Co., Ltd. | 機能性脳疾患治療剤 |
WO2009038110A1 (ja) | 2007-09-19 | 2009-03-26 | Nagoya Industrial Science Research Institute | 神経栄養因子様作用剤 |
JPWO2007125913A1 (ja) * | 2006-04-26 | 2009-09-10 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤 |
WO2012060396A1 (ja) | 2010-11-02 | 2012-05-10 | 財団法人名古屋産業科学研究所 | トランス-2-デセン酸誘導体及びこれを含有する医薬 |
CN102115429B (zh) * | 2010-01-06 | 2013-02-27 | 中国科学院上海药物研究所 | (e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途 |
JP2017214305A (ja) * | 2016-05-30 | 2017-12-07 | 岩手県 | 酸化ストレス抑制剤 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100797909B1 (ko) | 2006-09-07 | 2008-01-24 | 연세대학교 산학협력단 | 신경 줄기 세포 분화 유도 조성물 및 그것을 이용한 분화유도 방법 |
JP5807018B2 (ja) * | 2010-12-26 | 2015-11-10 | 和夫 酒井 | 新規医薬組成物及びその使用 |
JP7154586B2 (ja) * | 2016-02-23 | 2022-10-18 | ユニバーシティ-インダストリー コーオペレイション グループ オブ キョンヒ ユニバーシティ | 幹細胞の効能改善のための組成物及び方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0632008A1 (en) | 1993-06-01 | 1995-01-04 | Ono Pharmaceutical Co., Ltd. | Pentanoic acid derivatives |
JPH09238685A (ja) | 1996-03-07 | 1997-09-16 | Tanabe Seiyaku Co Ltd | 脳虚血関連遺伝子 |
JPH09263543A (ja) | 1996-03-29 | 1997-10-07 | Kazuhiro Ikenaka | ペプチド性分化促進剤 |
WO2001039779A1 (en) | 1999-12-01 | 2001-06-07 | Ucb, S.A. | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
JP2002097158A (ja) | 2000-07-18 | 2002-04-02 | Ono Pharmaceut Co Ltd | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 |
JP2002308779A (ja) | 2001-04-13 | 2002-10-23 | Gencom Co | 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び/又は生存の促進のための薬剤 |
WO2002102989A2 (en) | 2001-06-18 | 2002-12-27 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using valproate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431833A (en) * | 1982-12-27 | 1984-02-14 | American Cyanamid Company | Prostaglandin and hydroxylated fatty acid ester formulations |
-
2004
- 2004-10-01 JP JP2005514504A patent/JP4715514B2/ja not_active Expired - Fee Related
- 2004-10-01 US US10/574,479 patent/US8569058B2/en not_active Expired - Fee Related
- 2004-10-01 WO PCT/JP2004/014879 patent/WO2005032535A1/ja active Application Filing
- 2004-10-01 EP EP04792173A patent/EP1685832B1/en not_active Not-in-force
- 2004-10-01 AT AT04792173T patent/ATE504295T1/de not_active IP Right Cessation
- 2004-10-01 DE DE602004032165T patent/DE602004032165D1/de active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0632008A1 (en) | 1993-06-01 | 1995-01-04 | Ono Pharmaceutical Co., Ltd. | Pentanoic acid derivatives |
JPH07316092A (ja) | 1993-06-01 | 1995-12-05 | Ono Pharmaceut Co Ltd | ペンタン酸誘導体、その製造方法およびそれらを含有する薬剤 |
JPH09238685A (ja) | 1996-03-07 | 1997-09-16 | Tanabe Seiyaku Co Ltd | 脳虚血関連遺伝子 |
JPH09263543A (ja) | 1996-03-29 | 1997-10-07 | Kazuhiro Ikenaka | ペプチド性分化促進剤 |
WO2001039779A1 (en) | 1999-12-01 | 2001-06-07 | Ucb, S.A. | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
JP2002097158A (ja) | 2000-07-18 | 2002-04-02 | Ono Pharmaceut Co Ltd | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 |
JP2002308779A (ja) | 2001-04-13 | 2002-10-23 | Gencom Co | 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び/又は生存の促進のための薬剤 |
WO2002102989A2 (en) | 2001-06-18 | 2002-12-27 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using valproate |
Non-Patent Citations (3)
Title |
---|
CELL, vol. 97, no. 6, 11 June 1999 (1999-06-11), pages 703 - 716 |
DOETSCH F. ET AL.: "Subventricular zone astrocytes are neutral stem cells in the adult mammalian brain", CELL, vol. 97, 1999, pages 703 - 716, XP000942009 * |
PRUSINERY ET AL., J. CEREB. BLOOD FLOW METAB., vol. 6, 1979, pages 973 - 980 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1938814A1 (en) * | 2005-10-18 | 2008-07-02 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis |
EP1938814A4 (en) * | 2005-10-18 | 2009-06-03 | Ono Pharmaceutical Co | PHARMACEUTICAL PRODUCT FOR PROTECTING MOTOR NERVE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS |
WO2007046347A1 (ja) | 2005-10-18 | 2007-04-26 | Ono Pharmaceutical Co., Ltd. | 筋萎縮性側索硬化症患者の運動神経保護用医薬 |
EP1997486A4 (en) * | 2006-03-09 | 2010-03-24 | Ono Pharmaceutical Co | THERAPEUTIC AGENT AGAINST FUNCTIONAL BRAIN DISEASE |
WO2007102571A1 (ja) | 2006-03-09 | 2007-09-13 | Ono Pharmaceutical Co., Ltd. | 機能性脳疾患治療剤 |
EP1997486A1 (en) * | 2006-03-09 | 2008-12-03 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for functional brain disease |
US9517221B2 (en) | 2006-03-09 | 2016-12-13 | Ono Pharmaceutical Co., Ltd. | (2R)-2-propyloctanoic acid for functional brain disease |
JPWO2007125913A1 (ja) * | 2006-04-26 | 2009-09-10 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤 |
JP5695293B2 (ja) * | 2006-04-26 | 2015-04-01 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤 |
EP2457567A1 (en) | 2007-09-19 | 2012-05-30 | Nagoya Industrial Science Research Institute | Agent having neurotrophic factor-like activity |
US8557864B2 (en) | 2007-09-19 | 2013-10-15 | Nagoya Industrial Science Research Institute | Agent having neurotrophic factor-like activity |
WO2009038110A1 (ja) | 2007-09-19 | 2009-03-26 | Nagoya Industrial Science Research Institute | 神経栄養因子様作用剤 |
CN102115429B (zh) * | 2010-01-06 | 2013-02-27 | 中国科学院上海药物研究所 | (e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途 |
WO2012060396A1 (ja) | 2010-11-02 | 2012-05-10 | 財団法人名古屋産業科学研究所 | トランス-2-デセン酸誘導体及びこれを含有する医薬 |
US8987486B2 (en) | 2010-11-02 | 2015-03-24 | Nagoya Industrial Science Research Institute | Trans-2-decenoic acid derivative and pharmaceutical agent containing the same |
JP2017214305A (ja) * | 2016-05-30 | 2017-12-07 | 岩手県 | 酸化ストレス抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005032535A1 (ja) | 2006-12-14 |
EP1685832A4 (en) | 2009-01-07 |
DE602004032165D1 (de) | 2011-05-19 |
ATE504295T1 (de) | 2011-04-15 |
US8569058B2 (en) | 2013-10-29 |
JP4715514B2 (ja) | 2011-07-06 |
EP1685832A1 (en) | 2006-08-02 |
US20070043114A1 (en) | 2007-02-22 |
EP1685832B1 (en) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11679095B2 (en) | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | |
US20100254951A1 (en) | Nerve Regeneration Promoting Agent | |
WO2008100449A4 (en) | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury | |
JP5240757B2 (ja) | 神経再生促進剤 | |
KR20150008160A (ko) | 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 신규 옥시스테롤 유사체 oxy149 | |
US8921340B2 (en) | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions | |
WO2005032535A1 (ja) | 神経再生促進剤 | |
US20100004244A1 (en) | Use of cb2 receptor agonists for promoting neurogenesis | |
US20220226270A1 (en) | Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use | |
EP4236774A1 (en) | Methods of treating and preventing neurodegenerative diseases with hgf activating compounds | |
JP4788999B2 (ja) | 分枝鎖カルボン酸化合物およびその用途 | |
JP2012046543A (ja) | 神経変性疾患の予防および/または治療方法 | |
US20230000943A1 (en) | Method of inducing synaptogenesis by administering angiotensin and analogues thereof | |
JP5630264B2 (ja) | 膀胱排尿筋収縮および尿道括約筋弛緩剤 | |
JP2011513488A (ja) | 眼関連障害の治療 | |
JP6801704B2 (ja) | ヘキサデセン酸誘導体 | |
JP2006016318A (ja) | 2−プロピルオクタン酸の脳移行性向上プロドラッグおよびその用途 | |
JP4848117B2 (ja) | 副腎脳白質ジストロフィーを予防および治療するためのリルゾールもしくはその塩の使用 | |
JP5170926B2 (ja) | 運動ニューロン疾患を予防そして処置するためのエルゴリン及びリルゾールの組み合わせ物 | |
US20080312326A1 (en) | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | |
JP2006016319A (ja) | プロドラッグ | |
WO2001010445A1 (fr) | Remedes contre la neuropathie | |
Yorek | Articles in PresS. J Neurophysiol (April 29, 2015). doi: 10.1152/jn. 00224.2015 | |
JP2007039413A (ja) | (2s)−2−プロペニルオクタン酸または(2s)−2−プロピニルオクタン酸とアミンとからなる結晶 | |
WO2004019981A1 (ja) | 非神経細胞の神経細胞への分化成熟法、該剤と該剤探索法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514504 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004792173 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004792173 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007043114 Country of ref document: US Ref document number: 10574479 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10574479 Country of ref document: US |